Vineet Gupta

Vineet Gupta
File:GuptaVineet 10oct2025.jpgFile:GuptaVineet_10oct2025.jpg File:GuptaVineet_10oct2025.jpg
Born	September 23, 1969 (1969-09-23) (age 56) Dehradun, India
🏳️ Nationality	American
🎓 Alma mater	Indian Institute of Technology, Delhi, University of Rochester
💼 Occupation
🏅 Awards	Distinguished Award (The Society of Asian American Scientists in Cancer Research – SAASCR, 2019)
🌐 Website	Gupta Lab @ UTMB Galveston

Vineet Gupta (born September 23, 1969, in Dehradun, India) is an American drug discovery scientist, educator, and entrepreneur. He is recognized for his pioneering research on integrin agonists as a novel mechanism to target these receptors and develop novel therapeutics. Gupta serves as the inaugural Vice President for Innovation & Technology Development and Transfer at the University of Texas Medical Branch (UTMB) in Galveston, Texas, where he leads the institution’s Innovation mission area. He is also the Warmoth Endowed Professor of Hematology in the John Sealy School of Medicine, a Professor in the Division of Nephrology, Department of Internal Medicine, a Full Member of the Human Pathophysiology and Translational Medicine (HPTM) Graduate Program, and an Associate Member in the Department of Biochemistry, Cellular and Molecular Biology. He is a Distinguished Fellow in the Moody Brain Health Institute. He also serves as the CEO of Medical Branch Innovations, Inc., a UTMB subsidiary for venture and startup creation.

Early life and education

Gupta grew up in Dehradun, India. He earned his Bachelor of Science in chemistry from Delhi University. He received his M.S. in chemistry from Indian Institute of Technology, Delhi (IIT Delhi) and his Ph.D. in chemistry in the laboratory of professor Eric Kool at the University of Rochester in Rochester, New York, where his dissertation focused on self-cleaving DNA nucleosides. Gupta then completed postdoctoral training at the Rockefeller University in New York City as a Leukemia Research Foundation postdoctoral fellow, before holding positions in the biotechnology industry and returning to academia as a Fellow in Medicine at the Harvard Medical School-affiliated Massachusetts General Hospital (MGH).

Career

Gupta began his independent academic career in the Renal Unit at Massachusetts General Hospital in mid-2000s, serving as an Instructor and later Assistant Professor in Medicine at Harvard Medical School. At MGH, he co-initiated the Chemical Biology program and the Glomerular Disease program and was a Full Member of the Dana–Farber/Harvard Cancer Center Prostate Cancer Program .

In 2008, he joined the Division of Nephrology and Hypertension at the University of Miami Miller School of Medicine, where he directed the Peggy and Harold Katz Family Drug Center . In December 2012, he was recruited to Rush University Medical Center, where he served as Vice Chair for Research and Innovation in Internal Medicine, Director of the Drug Discovery Center, and the Charles Arthur Weaver Endowed Chair of Cancer Research .

Gupta has also co-founded several biotech startups to further develop his discoveries into innovations that can benefit patients. These include 149 Bio, LLC (operating as Allosite Therapeutics), where he is a co-founder and Scientific Officer, Adhaere Pharmaceuticals, Inc. (acquired by Gossamer Bio, Inc.) and Aquatrove Biosciences, Inc. (acquired by Sasmar Pharmaceuticals). Earlier, he was a senior scientist at Motorola Life Sciences, staff scientist and project leader at PerkinElmer Life Sciences, and Vice President and Chief Scientific Officer at GeneVention, LLC.

Scientific contributions

Gupta’s research centers on integrin biology and the translation of these findings into therapeutic development. His laboratory was among the first to propose pharmacological activation of integrins as a therapeutic strategy. His team first focused on the leukocyte integrin CD11b/CD18, to modulate inflammation and cancer .

Gupta holds over 50 patents and patent applications, including key innovations in integrin modulation and multiplex tissue analysis. He has translated laboratory discoveries into clinical applications, including the development of small molecules for lupus nephritis, systemic lupus, and cancer, several of which are in clinical trials. He co-founded Adhaere Pharmaceuticals to advance integrin-targeting therapies, leading to the development of GB1275, now in Phase I/II trials in partnership with Gossamer Bio and Merck.

Selected publications

• Li, Xiaobo; Villanueva, Veronica; Jimenez, Viviana; Nguyen, Billy; Chauhan, Nishant Ranjan; Khan, Samia Q; Dorschner, Jessica M; Jensen, Mark A; Alzahrani, Khulood; Wei, Huiting; Cimbaluk, David J; Wei, David C; Jolly, Meenakshi; Lopez-Rodriguez, Darlah; Pineda, Santiago Balza; Barbosa, Antonio; Vazquez-Padron, Roberto I; Faridi, Hafeez M; Reiser, Jochen; Niewold, Timothy B; Gupta, Vineet (2024). CD11b suppresses TLR7-driven inflammatory signaling to protect against lupus nephritis (Preprint). doi:10.1101/2024.07.26.605143. PMC 11361177 . PMID 39211173 .
• Venkatesh, Ishwarya; Shaw, Ameera M; Vattikota, Anirudh; Kamaraj, Sowmya Gurusamy; Youssef, Mohamed A; Li, Xiaobo; Varma, Disha; Killinger, Bryan A; Harms, Ashley; Kordower, Jeffrey; Gupta, Vineet (2024). Brain seqstain protocol (Preprint). doi:10.17504/protocols.io.261gedmdyv47/v1.
• Liu, Xiuting; Hogg, Graham D; Zuo, Chong; Borcherding, Nicholas C; Baer, John M; Lander, Varintra E; Kang, Liang-I; Knolhoff, Brett L; Ahmad, Faiz; Osterhout, Robin E; Galkin, Anna V; Bruey, Jean-Marie; Carter, Laura L; Mpoy, Cedric; Vij, Kiran R; Fields, Ryan C; Schwarz, Julie K; Park, Haeseong; Gupta, Vineet; DeNardo, David G (2023). "Context-dependent activation of STING-interferon signaling by CD11b agonists enhances anti-tumor immunity". Cancer Cell. 41 (6): 1073–1090. doi:10.1016/j.ccell.2023.04.018. PMC 10281762 . PMID 37236195 .
• Li, Xiaobo; Venkatesh, Ishwarya; Villanueva, Veronica; Wei, Huiting; Geraghty, Terese; Rajagopalan, Anugraha; Helmuth, Richard W; Altintas, Mehmet M; Faridi, Hafeez M; Gupta, Vineet (2022). "Podocyte-specific deletion of miR-146a increases podocyte injury and diabetic kidney disease". Frontiers in Medicine. 9. doi:10.3389/fmed.2022.897188. PMC 9433550 . PMID 36059820 .

Selected patents

• "Reagents and assays using modified integrin domains", US12291562B2, 2025 .
• "Sequential staining for multiplex analyses of tissues and cells", US12091706B2, 2024 .
• "Compounds and methods for regulating integrins", CA2882853C, 2021 .

External links

• Gupta Lab guptalab.com

This article "Vineet Gupta" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Vineet Gupta. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.

📰 Article(s) of the same category(ies)

• Lynda Stuart
• Austin A. Robinson
• Gautam Dagar
• Jeffrey H. Miller
• Randhir Jaiswal
• Josh Bonkowsky
• Andrew Boysen, Jr.

---